ramosetron has been researched along with Breast Cancer in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baek, SH; Baik, SW; Kim, CH; Kim, HK; Kim, KH; Kwon, JY; Lee, HJ; Shin, SW | 1 |
Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K | 1 |
2 trial(s) available for ramosetron and Breast Cancer
Article | Year |
---|---|
Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients.
Topics: Administration, Oral; Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Antiemetics; Benzimidazoles; Breast Neoplasms; Female; Fentanyl; Humans; Middle Aged; Pain Measurement; Patient Satisfaction; Postoperative Nausea and Vomiting; Premedication; Serotonin Antagonists; Treatment Outcome | 2008 |
[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Appetite; Benzimidazoles; Breast Neoplasms; Breast Neoplasms, Male; Cisplatin; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Nausea; Safety; Serotonin Antagonists; Treatment Outcome; Vomiting | 1999 |